A phase I and pharmacologic study of pyrazoloacridine (NSC 366140) and carboplatin in patients with advanced cancer

Investigational New Drugs

Volumn 20, Issue 3, 2002, Pages 297-304

  Adjei, Alex A ^a   Reid, Joel M ^a   Erlichman, Charles ^a   Sloan, Jeff A ^a   Pitot, Henry C ^a   Alberts, Steven R ^a   Goldberg, Richard M ^a   Hanson, Lorelei J ^a   Ruben, Stacie ^a   Boerner, Scott A ^a   Atherton, Pamela ^a   Ames, Matthew M ^a   Kaufmann, Scott H ^a  

^a MAYO CLINIC   (United States)

Author keywords

Phase I; Platinum; Pyrazoloacridine; Topoisomerases

Indexed keywords

2 (2 DIMETHYLAMINOETHYL) 9 METHOXY 5 NITROPYRAZOLO[3,4,5 KL]ACRIDINE; CARBOPLATIN; ACRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; PLATINUM; PYRAZOLE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DNA ADDUCT; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; LEUKOPENIA; MALE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MONONUCLEAR CELL; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; CHEMICALLY INDUCED DISORDER; DRUG INTERACTION; FOLLOW UP; METABOLISM; MIDDLE AGED; NEOPLASM;

ACRIDINES; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; DNA ADDUCTS; DRUG INTERACTIONS; FEMALE; FOLLOW-UP STUDIES; HUMAN; MALE; MIDDLE AGE; NEOPLASMS; NEUTROPENIA; PLATINUM; PYRAZOLES; SUPPORT, U.S. GOV'T, P.H.S.; HUMANS; MIDDLE AGED;

EID: 0036021218     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016237426846     Document Type: Article

References (21)

1. Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II
2. Pyrazoloacridines, a new class of antitumor agents with selectivity against solid tumors in vitro
3. Antitumor efficacy of PD 115932 (NSC 366140) against solid tumors of mice
4. Activity of the pyrazoloacridines against multidrug-resistant tumor cells
5. Patterns of cross-resistance in a multidrug-resistance small cell lung carcinoma line
6. Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single and multiple dosing schedules
7. Phase I clinical trial of pyrazoloacridine NSC366140 (PD 115934)
8. Phase I trial of pyrazoloacridine (PZA), a potent DNA binding agent, given as a weekly 24 hour continuous intravenous infusion in adult patients with refractory solid tumors
9. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers
10. Clinical trials referral resource. Clinical trials with pyrazoloacridine
11. Current status of pyrazoloacridine as an anticancer agent
12. Cytotoxic synergy between pyrazoloacridine (NSC366140) and cisplatin in vitro: Inhibition of platinum-DNA adduct removal
13. Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents
14. Murine pharmacokinetics of 6-aminonicotinamide (NSC 21206), a novel biochemical modulating agent
15. Analysis based on statistical moment theory
16. Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma
17. Pyrazoloacridine for the treatment of hormone-refractory prostate cancer
18. Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma
19. Phase II trials of pyrazoloacridine (NSC 366140) in patients with advanced hepatobiliary and pancreatic cancer
20. The pyrazoloacridines: Approaches to the development of a carcinoma-selective cytotoxic agent
21. The problem of the quiescent cancer cell